NCT00743483 - Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Cystic FibrosisExocrine Pancreatic Insufficiency

Interventions

DRUG

rhBSSL

oral suspension, 170 mg BSSL, 3 times daily for 5-6 days

Trial Locations (4)

Erasmus Medical Center, Rotterdam

Specjalistyczny Zespól Opieki Zdrowotnej nad Matka i Dzieckiem w Gdansku, Gdansk

Uniwersytet Medyczny im. K. Marcinkowskiego, Poznan

Oddzialu Terenowego Instytutu, Gruzlicy i Chorob Pluc w Rabce-Zdroju, Rabka-Zdrój